Literature DB >> 21714002

Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.

Stewart A Factor1, N Kyle Steenland, Donald S Higgins, Eric S Molho, Denise M Kay, Jennifer Montimurro, Ami R Rosen, Cyrus P Zabetian, Haydeh Payami.   

Abstract

Our aim was to examine disease-related and genetic correlates of the development of psychotic symptoms in a large population of patients with Parkinson's disease. We studied 500 patients with Parkinson's disease from the NeuroGenetics Research Consortium using logistic regression models. Predictors were demographic, clinical (motor/nonmotor features), and genetic, measured as continuous or dichotomous variables. Continuous measures were divided into population-based tertiles. Results are given as odds ratios (95% confidence intervals) for dichotomous variables and by ascending tertile for continuous variables. Psychotic symptoms were associated with increasing age: 4.86 (1.62-14.30) and 6.25 (2.09-18.74) (test for trend: P = 0.01); and duration of disease: 3.81 (1.23-11.76) and 5.33 (1.68-16.89) (test for trend: P = 0.03). For nonmotor features, we demonstrated positive trends with depression: 1.31 (0.47-3.61) and 5.01 (2.04-12.33) (test for trend: P < 0.0001); cognitive dysfunction: 0.69 (0.26-1.84) and 2.51 (1.00-6.29) (test for trend: P = 0.03); and an excess for those with sleep disorders: 2.00 (1.03-3.89) (P = 0.04). Psychotic symptoms were not associated with tremor or postural instability scores, but there was an association with freezing of gait: 3.83 (1.67-8.75) (P < 0.002). Psychotic symptoms were not associated with the presence of any examined polymorphisms in the apolipoprotein, alpha-synuclein, or microtubule associated protein tau genes. This is the largest study to examine correlates of psychotic symptoms in Parkinson's disease. We discovered a novel association with freezing of gait. We demonstrated an association with depression and duration of disease, both of which were inconsistently related in previous studies, and confirmed the association with age, cognitive dysfunction, and sleep disorders.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21714002      PMCID: PMC4216677          DOI: 10.1002/mds.23806

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  48 in total

1.  Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.

Authors:  Hulya Apaydin; J Eric Ahlskog; Joseph E Parisi; Bradley F Boeve; Dennis W Dickson
Journal:  Arch Neurol       Date:  2002-01

2.  Risk of dementia in Parkinson's disease: a community-based, prospective study.

Authors:  D Aarsland; K Andersen; J P Larsen; A Lolk; H Nielsen; P Kragh-Sørensen
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

Review 3.  The management of the levodopa psychoses.

Authors:  J H Friedman
Journal:  Clin Neuropharmacol       Date:  1991-08       Impact factor: 1.592

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Prospective study of hallucinations and delusions in Parkinson's disease.

Authors:  S Holroyd; L Currie; G F Wooten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

6.  Longitudinal outcome of Parkinson's disease patients with psychosis.

Authors:  S A Factor; P J Feustel; J H Friedman; C L Comella; C G Goetz; R Kurlan; M Parsa; R Pfeiffer
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

7.  Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system.

Authors:  Jennifer G Goldman; Christopher G Goetz; Elizabeth Berry-Kravis; Sue Leurgans; Lili Zhou
Journal:  Arch Neurol       Date:  2004-08

8.  Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease.

Authors:  Jian Wang; Yan-Mei Si; Zhuo-Lin Liu; Long Yu
Journal:  Pharmacogenetics       Date:  2003-06

9.  Ophthalmologic features of Parkinson's disease.

Authors:  V Biousse; B C Skibell; R L Watts; D N Loupe; C Drews-Botsch; N J Newman
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

10.  L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.

Authors:  R Kaiser; A Hofer; A Grapengiesser; T Gasser; A Kupsch; I Roots; J Brockmöller
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

View more
  20 in total

Review 1.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

2.  Affective Correlates of Psychosis in Parkinson's Disease.

Authors:  Stewart A Factor; Michael K Scullin; Alan Freeman; Donald L Bliwise; William M McDonald; Felicia C Goldstein
Journal:  Mov Disord Clin Pract       Date:  2016-06-16

Review 3.  Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction.

Authors:  Marco Onofrj; Alberto J Espay; Laura Bonanni; Stefano Delli Pizzi; Stefano L Sensi
Journal:  Mov Disord       Date:  2019-07-15       Impact factor: 10.338

4.  Treatment of Parkinson's disease psychosis.

Authors:  Kevin J Black
Journal:  Med Int Rev       Date:  2018-02-03

Review 5.  Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Authors:  Shyam C Panchal; William G Ondo
Journal:  Curr Psychiatry Rep       Date:  2018-01-27       Impact factor: 5.285

6.  [Evidence-based treatment of psychosis associated with Parkinson's disease].

Authors:  R Haussmann; M Bauer; M Donix
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

Review 7.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 8.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

Review 9.  A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson's disease.

Authors:  Camilla Christina Pedersen; Johannes Lange; Marthe Gurine Gunnarsdatter Førland; Angus D Macleod; Guido Alves; Jodi Maple-Grødem
Journal:  NPJ Parkinsons Dis       Date:  2021-07-01

10.  Key issues in essential tremor genetics research: Where are we now and how can we move forward?

Authors:  Claudia M Testa
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.